Improving Drug Delivery with a Special Coating
Zwitterionic polyethylene glycol for therapeutic delivery
This project explores a new way to deliver medicines more effectively, helping them stay in the body longer and avoid unwanted immune responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Drexel University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11184344 on NIH RePORTER |
What this research studies
Many important medicines, like some vaccines and biologics, are coated with a substance called PEG to help them work better and stay in your system longer. However, some people have antibodies that fight against PEG, which can make these medicines less effective and even cause side effects. This research is developing a new type of coating, called zwitterionic polyethylene glycol, that aims to provide the same benefits as PEG without triggering these unwanted immune reactions. By creating a "stealthier" coating, this work hopes to make future drug treatments safer and more powerful for everyone.
Who could benefit from this research
Good fit: This foundational research does not directly involve patients but aims to benefit those who need medications that could be improved by better delivery systems.
Not a fit: Patients who do not require medications that utilize advanced delivery systems would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new and improved medications that are more effective and have fewer side effects for a wider range of patients.
How similar studies have performed: While PEGylated drugs are widely successful, the problem of anti-PEG antibodies is a known limitation, and this research explores a novel approach to overcome it.
Where this research is happening
Philadelphia, United States
- Drexel University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Cheng, Hao — Drexel University
- Study coordinator: Cheng, Hao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.